New hope for Tough-to-Treat skin cancers in clinical trial
NCT ID NCT07347444
Summary
This study is testing a new combination of two immunotherapy drugs (iparomlimab and tuvoraleimab) with three standard chemotherapy drugs for people with advanced acral or mucosal melanoma. The goal is to see if this five-drug combination can better control the cancer and is safe for patients. It is for adults who have had one or fewer prior treatments for their advanced melanoma.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACRAL MELANOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Fudan university cancer hospital
Shanghai, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.